Soleno Therapeutics, Inc. (SLNO)

Market Cap	2.72B +21.2%
Revenue (ttm)	190.41M
Net Income	20.48M
EPS	0.39
Shares Out	51.72M
PE Ratio	134.95
Forward PE	13.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,574,402
Open	52.50
Previous Close	52.51
Day's Range	52.48 - 52.69
52-Week Range	29.43 - 90.32
Beta	-2.80
Analysts	Buy
Price Target	90.13 (+71.25%)
Earnings Date	May 6, 2026

About SLNO

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 13, 2014
• Employees: 182
• Stock Exchange: NASDAQ
• Ticker Symbol: SLNO
• Website: https://soleno.life

Analyst Summary

According to 9 analysts, the average rating for SLNO stock is "Buy." The 12-month stock price target is $90.13, which is an increase of 71.25% from the latest price.

Price Target

$90.13

(71.25% upside)

Analyst Consensus: Buy